CHC Healthcare Group (TPE:4164)
27.30
+0.60 (2.25%)
Jul 21, 2026, 1:30 PM CST
CHC Healthcare Group Revenue
CHC Healthcare Group had revenue of 1.16B TWD in the quarter ending March 31, 2026, with 15.18% growth. This brings the company's revenue in the last twelve months to 4.55B, up 15.21% year-over-year. In the year 2025, CHC Healthcare Group had annual revenue of 4.40B with 22.15% growth.
Revenue (ttm)
4.55B
Revenue Growth
+15.21%
P/S Ratio
1.17
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.32B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.40B | 797.71M | 22.15% |
| Dec 31, 2024 | 3.60B | -276.56M | -7.13% |
| Dec 31, 2023 | 3.88B | 902.79M | 30.35% |
| Dec 31, 2022 | 2.97B | 534.79M | 21.92% |
| Dec 31, 2021 | 2.44B | -115.35M | -4.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 17.50B |
| Cenra | 8.54B |
| Formosa Optical Technology | 4.25B |
| Panion & Bf Biotech | 2.10B |
| SCI Pharmtech | 1.36B |
| Mycenax Biotech | 815.34M |
| Caliway Biopharmaceuticals | 38.04M |
| Pell Bio-Med Technology | 25.85M |